The aesthetic patient is changing—and the latest ASPS data gives practice owners important clues about where demand is headed. From healthy aging and GLP-1-related consultations to lasers, skin quality and comprehensive treatment planning, here's what med spa owners should be paying attention to now.

Patients are asking for retatrutide, but demand does not equal permission to sell it. Here’s what aesthetic practice owners need to know about retatrutide compliance—and why the bigger GLP-1 opportunity may be in treating the aesthetic changes that happen after the weight comes off.

The FDA's recent peptide advisory vote isn't a green light. Here's what every medspa owner should know before adding peptide therapies.